findmyKOL
Clinical trialNCT03712202Active, not recruitingPhase 2Interventional

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

SponsorCity of Hope Medical CenterEnrollment155Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage I Lymphocyte-Depleted Classic HLAnn Arbor Stage I Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage I Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin Lymphoma+8 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, United States

  • City of Hope Medical Center

    Duarte, California, United States

  • University of California San Diego

    San Diego, California, United States

  • Emory University Hospital/winship Cancer Institute

    Atlanta, Georgia, United States

  • Northwestern University

    Chicago, Illinois, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Massachusetts General Hospital

    Charlestown, Massachusetts, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, United States

  • Nyp/weill Cornell Medical Center

    New York, New York, United States

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

    Cleveland, Ohio, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

  • University of Pennsylvania/abramson Cancer Center

    Philadelphia, Pennsylvania, United States

  • Sarah Cannon Cancer Center

    Nashville, Tennessee, United States

  • M D Anderson Cancer Center

    Houston, Texas, United States

  • Huntsman Cancer Institute/university of Utah

    Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Nov 2018
Primary completion
23 Dec 2024
Completion
23 Dec 2024
Last update posted
6 Nov 2024
Registered enrollment
155
Registry id
NCT03712202

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.